title: Prognostic impact of ß-blocker use in patients with stable coronary artery disease.
abstract: OBJECTIVE
  To assess the association of ß-blocker use with cardiovascular mortality in patients with stable coronary artery disease (CAD).
  
  
  METHODS
  We analysed the data of 4184 outpatients included in a prospective cohort study on stable CAD. Two groups were formed based on ß-blocker use at enrolment. Two propensity score analyses were performed to control for differences in covariates: one with adjustment among the entire cohort, and the other with propensity score matching. The outcome variable was cardiovascular mortality after a 2-year follow-up.
  
  
  RESULTS
  There were 3320 patients with ß-blocker use. Younger age, hypertension, diabetes, prior myocardial infarction, multivessel CAD, prior coronary revascularisation, prior stroke, prior hospitalisation for heart failure and a low LVEF were associated with ß-blocker use. Clinical follow-up data were obtained for 4149 patients (99.2%). When adjusted on propensity score, ß-blocker use was associated with a HR for cardiovascular mortality of 0.64 (0.42-0.98) in the whole cohort (p=0.04). After one-to-one propensity score matching, both groups (n=839 in each group) were well matched on covariates. The cardiovascular mortality rate in the propensity-matched cohort was significantly lower in patients with ß-blocker use with a HR of 0.43 (0.22-0.82) (p=0.011). Non-cardiovascular mortality was similar in both groups. These results were consistent across different subgroups.
  
  
  CONCLUSIONS
  In this observational study of patients with stable CAD, the use of ß-blockers was associated with a lower risk of cardiovascular mortality.
authors.affiliation: Centre Hospitalier Régional et Universitaire de Lille, Lille, France Inserm U744, Institut Pasteur de Lille, Université Lille Nord de France, Lille, France Faculté de Médecine de Lille, Lille, France.
authors.forename: Christophe
authors.initials: C
authors.lastname: Bauters
authors.affiliation: Centre Hospitalier Régional et Universitaire de Lille, Lille, France Inserm U744, Institut Pasteur de Lille, Université Lille Nord de France, Lille, France Faculté de Médecine de Lille, Lille, France.
authors.forename: Gilles
authors.initials: G
authors.lastname: Lemesle
authors.affiliation: Polyclinique du Bois, Lille, France.
authors.forename: Thibaud
authors.initials: T
authors.lastname: Meurice
authors.affiliation: Centre Hospitalier de Dunkerque, Dunkerque, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Tricot
authors.affiliation: Centre Hospitalier Régional et Universitaire de Lille, Lille, France Inserm U744, Institut Pasteur de Lille, Université Lille Nord de France, Lille, France.
authors.forename: Pascal
authors.initials: P
authors.lastname: de Groote
authors.affiliation: Centre Hospitalier Régional et Universitaire de Lille, Lille, France Inserm U744, Institut Pasteur de Lille, Université Lille Nord de France, Lille, France Faculté de Médecine de Lille, Lille, France.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Lamblin
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage*; D000368:Aged; D015331:Cohort Studies; D016001:Confidence Intervals; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D018570:Risk Assessment; D012720:Severity of Illness Index; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists
keywords: Coronary Artery Disease